Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityIPAS / iPass, Inc. (46261V108)
IndustryComputer Processing and Data Preparation and Processing Services
Institutional Owners39
Institutional Shares13,830,285 - 16.47%
Common Shares Outstanding83,978,957 shares (as of 2018-06-30)
Institutional Value$ 5,399,000 USD

Institutional Stock Ownership and Shareholders()

IPAS / iPass, Inc. Institutional Ownership

iPass, Inc. (NASDAQ:IPAS) has 39 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 13,830,285 shares. Largest shareholders include Renaissance Technologies LLC, Vanguard Group Inc, Pratt Collard Advisory Partners Llc, Perkins Capital Management Inc, Manatuck Hill Partners, LLC, Goldman Capital Management Inc, Emancipation Management LLC, Geode Capital Management, Llc, Eidelman Virant Capital, and California Public Employees Retirement System.
iPass, Inc. (NASDAQ:IPAS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-13 13F-HR Manatuck Hill Partners, LLC 450,000 1,050,000 133.33 171 362 111.70
2018-08-14 13F-HR Invesco Ltd. 19,523 7
2018-08-09 13F-HR BlackRock Inc. 295,997 133,524 -54.89 112 46 -58.93
2018-08-14 13F-HR UBS Group AG 22,525 19,371 -14.00 8 7 -12.50
2018-07-18 13F-HR AMG National Trust Bank 49,570 49,570 0.00 19 17 -10.53
2018-08-14 13F-HR STATE STREET CORP 27,610 27,610 0.00 10 8 -20.00
2018-08-02 13F-HR PERKINS CAPITAL MANAGEMENT INC 1,642,471 566
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 26,934 67,078 149.05 10 23 130.00
2018-08-14 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 452,065 0 -100.00 172 0 -100.00
2018-08-13 13F-HR EARNEST PARTNERS LLC 7,700 7,700 0.00 3 3 0.00
2018-08-10 13F-HR Emancipation Management LLC 0 576,802 0 199
2018-08-10 13F-HR UNITED SERVICES AUTOMOBILE ASSOCIATION 12,564 12,564 0.00 5 4 -20.00
2017-10-26 13F-HR Acrospire Investment Management LLC 2,642 0 -100.00 3 0 -100.00
2017-02-10 13F-HR BlackRock Investment Management, LLC 11,385 11,385 0.00 19 19 0.00
2018-08-14 13F-HR Adirondack Research & Management Inc. 814,742 30,366 -96.27 310 10 -96.77
2018-08-07 13F-HR Marathon Capital Management 42,035 50,000 18.95 15 17 13.33
2018-08-14 13F-HR One Wealth Advisors, Llc 76,700 76,700 0.00 29 26 -10.34
2018-08-14 13F-HR GUGGENHEIM CAPITAL LLC 23,735 0 -100.00 9 0 -100.00
2018-08-17 13F-HR/A NOMURA HOLDINGS INC 41,226 41,226 0.00 16 14 -12.50
2018-08-13 13F-HR Renaissance Technologies LLC 3,291,898 1,251
2018-08-14 13F-HR MORGAN STANLEY 61 686 1,024.59 0 0
2018-08-13 13F-HR Advisor Group, Inc. 0 8,800 0 3
2018-08-08 13F-HR M&R CAPITAL MANAGEMENT INC 15,000 15,000 0.00 5 5 0.00
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 86,574 86,574 0.00 141 143 1.42
2018-07-20 13F-HR Creative Planning 30,000 30,000 0.00 11 10 -9.09
2018-08-10 13F-HR GABELLI FUNDS LLC 50,000 0 -100.00 19 0 -100.00
2018-07-25 13F-HR Pratt Collard Advisory Partners Llc 1,654,520 1,790,120 8.20 629 617 -1.91
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 351,470 351,470 0.00 134 121 -9.70
2018-08-15 13F-HR JANE STREET GROUP, LLC 0 32,291 0 11
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 38,738 38,738 0.00 51 26 -49.02
2018-08-14 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 99,900 95,300 -4.60 38 33 -13.16
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 0 0 0 0
2018-07-24 13F-HR Mccollum Christoferson Group Llc 40,000 65,000 62.50 15 22 46.67
2018-08-21 13F-HR Paragon Capital Management Ltd 16,667 16,667 0.00 6 6 0.00
2018-08-06 13F-HR Bank of New York Mellon Corp 66,541 53,977 -18.88 26 19 -26.92
2017-02-10 13F-HR BlackRock Fund Advisors 177,212 182,136 2.78 289 301 4.15
2018-07-24 13F-HR Eidelman Virant Capital 650,000 400,000 -38.46 247 137 -44.53
2018-07-31 13F-HR Commonwealth Equity Services, Llc. 48,738 48,738 0.00 18 17 -5.56
2018-08-09 13F-HR Royce & Associates LLC 948,500 0 -100.00 360 0 -100.00
2018-08-14 13F-HR Capital Bank & Trust Co 7,035 7,035 0.00 3 2 -33.33
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 474,363 474,363 0.00 180 163 -9.44
2018-02-14 13F-HR GOLDMAN CAPITAL MANAGEMENT INC 1,301,000 801,000 -38.43 859 417 -51.46
2018-08-14 13F-HR VANGUARD GROUP INC 2,297,739 2,055,405 -10.55 873 709 -18.79
2018-08-14 13F-HR WHITE PINE CAPITAL LLC 35,000 35,000 0.00 13 12 -7.69
2018-08-14 13F-HR NORTHERN TRUST CORP 134,197 134,197 0.00 51 46 -9.80

Related Articles

REPH: Recro Pharma Analysis and Research Report

2018-08-20 - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

2018-08-20 - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

2018-08-20 - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...

Related News Stories

iPass Inc. 2018 Q2 - Results - Earnings Call Slides

2018-08-09 seekingalpha
The following slide deck was published by iPass Inc. in conjunction with their 2018 Q2 earnings call. (2-2)

iPass Inc. (IPAS) CEO Gary Griffiths on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Good day. And welcome to the iPass Inc. Second Quarter 2018 Financial Results Conference Call. Today's conference is being recorded. (3-2)

iPass' (IPAS) CEO Gary Griffiths on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day. And welcome to the iPass First Quarter 2018 Financial Results Conference Call. Today's conference is being recorded. (15-0)

iPass Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-09 seekingalpha
The following slide deck was published by iPass Inc. in conjunction with their 2018 Q1 earnings call. (15-1)

BRIEF-Ipass Announces A Deal With Lycamobile To Provide Global Wi-Fi To Its Monthly Plan Customers

2018-04-16 reuters
* IPASS INC - ANNOUNCED A DEAL WITH LYCAMOBILE TO PROVIDE GLOBAL WI-FI TO ITS MONTHLY PLAN CUSTOMERS (15-4)

Silicon Investor Message Boards

This table lists all message boards related to IPAS / iPass, Inc. on message board site Silicon Investor.

iPASS Stock Discussion iPASS Stock Discussion iPASS Stock Discussion
CUSIP: 46261V108